- Home
- HST vs BBIO Comparison
HST vs BBIO Comparison
Compare HST & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HST | BBIO |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8B | 15.3B |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HST | BBIO |
|---|---|---|
| Price | $19.20 | $65.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 23 |
| Target Price | $18.96 | ★ $82.26 |
| AVG Volume (30 Days) | ★ 8.5M | 2.8M |
| Earning Date | 05-21-2026 | 05-22-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $5,387,000,000.00 | $502,076,000.00 |
| Revenue This Year | N/A | $88.86 |
| Revenue Next Year | $1.19 | $74.11 |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $12.27 | $28.33 |
| 52 Week High | $21.00 | $84.94 |
Technical Indicators
Market Signals| Indicator | HST | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 38.40 |
| Support Level | $17.15 | $61.54 |
| Resistance Level | $21.00 | $68.71 |
| Average True Range (ATR) | 0.65 | 3.02 |
| MACD | -0.13 | -0.20 |
| Stochastic Oscillator | 27.94 | 20.56 |
Price Performance
Historical ComparisonAbout HST Host Hotels & Resorts Inc.
Host Hotels & Resorts owns 80 predominantly urban and resort upper-upscale and luxury hotel properties representing nearly 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.